AtriCure (ATRC) Scheduled to Post Earnings on Tuesday

AtriCure (NASDAQ:ATRC) is scheduled to be releasing its earnings data after the market closes on Tuesday, February 18th. Analysts expect AtriCure to post earnings of ($0.41) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Shares of AtriCure stock opened at $43.84 on Monday. The firm has a 50-day moving average of $36.83 and a 200-day moving average of $30.16. The stock has a market cap of $1.70 billion, a PE ratio of -73.07 and a beta of 0.29. AtriCure has a 52-week low of $22.57 and a 52-week high of $44.32. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.49 and a current ratio of 3.11.

In related news, COO Douglas J. Seith sold 36,363 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $34.00, for a total transaction of $1,236,342.00. Following the completion of the sale, the chief operating officer now owns 131,743 shares of the company’s stock, valued at $4,479,262. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael H. Carrel sold 23,546 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $33.00, for a total transaction of $777,018.00. Following the sale, the chief executive officer now directly owns 650,036 shares of the company’s stock, valued at approximately $21,451,188. The disclosure for this sale can be found here. Insiders have sold 250,219 shares of company stock valued at $9,054,763 in the last ninety days. 8.00% of the stock is currently owned by company insiders.

A number of brokerages have recently issued reports on ATRC. BTIG Research began coverage on shares of AtriCure in a research report on Thursday, February 6th. They issued a “buy” rating and a $42.00 target price for the company. Piper Sandler reissued a “buy” rating and issued a $40.00 target price on shares of AtriCure in a research report on Monday, January 27th. Zacks Investment Research cut shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Tuesday, December 31st. Needham & Company LLC reissued a “buy” rating and issued a $48.00 target price (up previously from $39.00) on shares of AtriCure in a research report on Friday, January 24th. Finally, ValuEngine cut shares of AtriCure from a “buy” rating to a “hold” rating in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $38.86.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

Recommended Story: S&P 500 Index

Earnings History for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.